Europe - EPA:ALERS - FR0013240934 - Common Stock
The current stock price of ALERS.PA is 24.45 EUR. In the past month the price decreased by -1.01%. In the past year, price decreased by -5.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.08 | 48.01B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 24.38 | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
EUROBIO-SCIENTIFIC
ZA de Courtaboeuf 7 Avenue de Scandinavie, Les Ulis Cedex
Les Ulis ILE-DE-FRANCE FR
Employees: 329
Phone: 331169796480
Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
The current stock price of ALERS.PA is 24.45 EUR. The price increased by 0.62% in the last trading session.
ALERS.PA does not pay a dividend.
ALERS.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
The PE ratio for EUROBIO-SCIENTIFIC (ALERS.PA) is 106.3. This is based on the reported non-GAAP earnings per share of 0.23 and the current share price of 24.45 EUR.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALERS.PA.
EUROBIO-SCIENTIFIC (ALERS.PA) has a market capitalization of 250.61M EUR. This makes ALERS.PA a Micro Cap stock.
ChartMill assigns a technical rating of 1 / 10 to ALERS.PA. When comparing the yearly performance of all stocks, ALERS.PA is a bad performer in the overall market: 80.8% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA. ALERS.PA has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months ALERS.PA reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS decreased by -63.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.46% | ||
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| Debt/Equity | 0.07 |
9 analysts have analysed ALERS.PA and the average price target is 30.6 EUR. This implies a price increase of 25.15% is expected in the next year compared to the current price of 24.45.
For the next year, analysts expect an EPS growth of -11.36% and a revenue growth 22.03% for ALERS.PA